Madrigal Pharmaceuticals, Inc. (LON:0JXI)

London flag London · Delayed Price · Currency is GBP · Price in USD
308.21
+15.15 (5.17%)
At close: Jun 27, 2025
12.79%
Market Cap 4.87B
Revenue (ttm) 245.65M
Net Income (ttm) -303.09M
Shares Out n/a
EPS (ttm) -13.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 55
Average Volume 58
Open 301.54
Previous Close 293.06
Day's Range 301.54 - 308.60
52-Week Range 201.25 - 375.14
Beta -0.76
RSI 62.49
Earnings Date Aug 5, 2025

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
CEO William Sibold
Employees 528
Stock Exchange London Stock Exchange
Ticker Symbol 0JXI
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.